Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn’s disease—the devil is in the detail

Ashish Srinivasan, Peter De Cruz, Daniel R. van Langenberg

Research output: Contribution to journalLetterOtherpeer-review

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)561-562
Number of pages2
JournalAlimentary Pharmacology and Therapeutics
Issue number3
Publication statusPublished - 1 Aug 2020

Cite this